Related references
Note: Only part of the references are listed.Current and emerging treatment modalities for metastatic castration-resistant prostate cancer
Sergio Bracarda et al.
BJU INTERNATIONAL (2011)
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors: Exploiting a Synthetic Lethal Strategy in the Clinic
Timothy A. Yap et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
A Phase 2 Study of Estramustine, Docetaxel, and Bevacizumab in Men With Castrate-Resistant Prostate Cancer Results From Cancer and Leukemia Group B Study 90006
Joel Picus et al.
CANCER (2011)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
David J. Mulholland et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Small Molecule Inhibitors Targeting the Achilles' Heel of Androgen Receptor Activity
Marianne D. Sadar
CANCER RESEARCH (2011)
Utilizing circulating tumor cells: challenges and pitfalls
Gerhardt Attard et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2011)
Eight-Signature Classifier for Prediction of Nasopharnyngeal Carcinoma Survival
Hai-Yun Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High-Dose Methotrexate-Induced Renal Dysfunction: Is Glucarpidase Necessary for Rescue? Reply
Brigitte C. Widemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Validation of a New Risk Assessment Model for Predicting Adverse Events in Children With Fever and Chemotherapy-Induced Neutropenia
Karin G. E. Miedema et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
Richard D. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BRAF targeted therapy changes the treatment paradigm in melanoma
Antoni Ribas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
A decade in prostate cancer: from NMR to metabolomics
Elita M. DeFeo et al.
NATURE REVIEWS UROLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
Evan Y. Yu et al.
UROLOGY (2011)
A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
Srikala S. Sridhar et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
G. Sonpavde et al.
ANNALS OF ONCOLOGY (2010)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L. R. Molife et al.
ANNALS OF ONCOLOGY (2010)
20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth
Manolis A. Fousteris et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
Jean-Christophe Eymard et al.
BJU INTERNATIONAL (2010)
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial
Nicholas D. James et al.
BJU INTERNATIONAL (2010)
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L. R. Molife et al.
BRITISH JOURNAL OF CANCER (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Aberrant Activation of the Androgen Receptor by NF-κB2/p52 in Prostate Cancer Cells
Nagalakshmi Nadiminty et al.
CANCER RESEARCH (2010)
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Meng-Lei Zhu et al.
CANCER RESEARCH (2010)
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
William P. Tew et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
Jose Baselga et al.
CLINICAL CANCER RESEARCH (2010)
Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
Masuo Yamaoka et al.
CLINICAL CANCER RESEARCH (2010)
Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff et al.
CLINICAL CANCER RESEARCH (2010)
Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer
B. Wegiel et al.
CURRENT CANCER DRUG TARGETS (2010)
RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?
H. C. Whitaker et al.
CURRENT CANCER DRUG TARGETS (2010)
Estimates of cancer incidence and mortality in Europe in 2008
J. Ferlay et al.
EUROPEAN JOURNAL OF CANCER (2010)
被撤回的出版物: Horizon scanning for novel therapeutics for the treatment of prostate cancer (Retracted article. See vol. 21, pg. 1591, 2012)
Diletta Bianchini et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor
X. Edward Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer
Ryan M. Franke et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
Yang-Min Ning et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Longitudinal Study of Depressive Symptoms in Patients With Metastatic Gastrointestinal and Lung Cancer
Christopher Lo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Daniel C. Danila et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H. M. Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
Howard I. Scher et al.
LANCET (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T
Celestia S. Higano et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prostate cancer as a model for tumour immunotherapy
Charles G. Drake
NATURE REVIEWS IMMUNOLOGY (2010)
Envisioning the future of early anticancer drug development
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2010)
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2009)
Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (National Cancer Institute Trial 6862) Trial Results and Interleukin-6 Analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
Deborah Bradley et al.
CANCER (2009)
Integrated Data From 2 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials of Active Cellular Immunotherapy With Sipuleucel-T in Advanced Prostate Cancer
Celestia S. Higano et al.
CANCER (2009)
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer
Jozsef Horti et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong et al.
CANCER RESEARCH (2009)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
CANCER RESEARCH (2009)
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
Glenn Liu et al.
CLINICAL CANCER RESEARCH (2009)
Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2009)
Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab Plus Doxorubicin in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Susan F. Slovin et al.
CLINICAL GENITOURINARY CANCER (2009)
Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
Nicholas D. James et al.
EUROPEAN UROLOGY (2009)
Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene
Claudine Legault et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
Yu Chen et al.
LANCET ONCOLOGY (2009)
Ligand-independent activation of the androgen receptor by insulin-like growth factor-i and the role of the MAPK pathway in skeletal muscle cells
Hye Jin Kim et al.
MOLECULES AND CELLS (2009)
PSA as an intermediate end point in clinical trials
Gerhardt Attard et al.
NATURE REVIEWS UROLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P. Harris et al.
NATURE CLINICAL PRACTICE UROLOGY (2009)
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
X. Pivot et al.
ANNALS OF ONCOLOGY (2008)
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones
Mary-Ellen Taplin et al.
BJU INTERNATIONAL (2008)
The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens
Liang Schweizer et al.
BMC CELL BIOLOGY (2008)
Fusion in the ETS gene family and prostate cancer
S. A. Narod et al.
BRITISH JOURNAL OF CANCER (2008)
Antiandrogen withdrawal in castrate-refractory prostate cancer
A. Oliver Sartor et al.
CANCER (2008)
Phase 3, Randomized, Controlled Trial of Atrasentan in Patients With Nonmetastatic, Hormone-Refractory Prostate Cancer
Joel B. Nelson et al.
CANCER (2008)
A phase II clinical trial of sorafenib in androgen-independent prostate cancer
William L. Dahut et al.
CLINICAL CANCER RESEARCH (2008)
A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2008)
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Elisabeth I. Heath et al.
CLINICAL CANCER RESEARCH (2008)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Targeting CYP17: established and novel approaches in prostate cancer
Timothy A. Yap et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Extramedullary Myeloid Sarcoma of the Breast (vol 26, pg 4041, 2008)
Hatem A. Azim et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: A randomized phase II trial
Francesco Boccardo et al.
ONCOLOGY (2008)
Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression
G. N. Brooke et al.
ONCOGENE (2008)
Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell
L. Leotoing et al.
ONCOGENE (2008)
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
K. N. Chi et al.
ANNALS OF ONCOLOGY (2008)
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
G. Attard et al.
ONCOGENE (2008)
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
Hans Lilja et al.
NATURE REVIEWS CANCER (2008)
Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy
Guru Sonpavde et al.
CLINICAL GENITOURINARY CANCER (2007)
Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: A randomized phase II study
Sophie D. Fossa et al.
EUROPEAN UROLOGY (2007)
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S. Steinbild et al.
BRITISH JOURNAL OF CANCER (2007)
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
Michael A. Carducci et al.
CANCER (2007)
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
Eric J. Small et al.
BJU INTERNATIONAL (2007)
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
Paul Mathew et al.
CLINICAL CANCER RESEARCH (2007)
Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development
Robert D. Bruno et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients - Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone
Jonathan E. Rosenberg et al.
CANCER (2007)
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation
Nupam P. Mahajan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The association between measures of progression and survival in castrate-metastatic prostate cancer
Howard I. Scher et al.
CLINICAL CANCER RESEARCH (2007)
The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression
Meletios Verras et al.
CANCER RESEARCH (2007)
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer
Marc Salzberg et al.
ONKOLOGIE (2007)
Inappropriate activation of the androgen receptor by nonsteroids: Involvement of the Src kinase pathway and its therapeutic implications
Sonal J. Desai et al.
CANCER RESEARCH (2006)
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
G. Attard et al.
BRITISH JOURNAL OF CANCER (2006)
Interaction of IGF signaling and the androgen receptor in prostate cancer progression
Jennifer D. Wu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Drug development in oncology: classical cytotoxics and molecularly targeted agents
Shivaani Kummar et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Predictors of mortality after prostate-specific antigen failure
Anthony V. D'Amico et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Autoantibody signatures in prostate cancer
XJ Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome
G Petrovics et al.
ONCOGENE (2005)
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model
VD Handratta et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group
CM Canil et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells
S Gao et al.
PROSTATE (2004)
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583)
EJ Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
A Ziada et al.
PROSTATE (2004)
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
J Holzbeierlein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance
B He et al.
MOLECULAR CELL (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Imatinib mesylate and zoledronic acid in an drogen-in dependent prostate cancer
NM Tiffany et al.
UROLOGY (2004)
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
J Edwards et al.
BRITISH JOURNAL OF CANCER (2003)
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function
B Comuzzi et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer
W Berry et al.
JOURNAL OF UROLOGY (2002)
Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone
M Morioka et al.
UROLOGIA INTERNATIONALIS (2002)
Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer
K Nishimura et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer
AW Tolcher
SEMINARS IN ONCOLOGY (2001)
Treatment of androgen-independent prostate cancer with dexamethasone: A prospective study in stage D2 patients
T Saika et al.
INTERNATIONAL JOURNAL OF UROLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
